Download PDF
Horm Metab Res 2020; 52(02): 77-84
DOI: 10.1055/a-1089-7710
Review
© Georg Thieme Verlag KG Stuttgart · New York

Phytoestrogens in NAFLD: Potential Mechanisms of Action

Hui Li
1   Department of Dentistry, Jilin University, Changchun, China
,
Erna Jia
2   Department of Gastroenterology and Hepatology, Jilin University, Changchun, China
,
Jian Jiao
2   Department of Gastroenterology and Hepatology, Jilin University, Changchun, China
› Author Affiliations Funding Information Natural Science Foundation of Jilin Province 2018.
Further Information

Publication History

received 19 March 2019

accepted 18 December 2019

Publication Date:
13 February 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Many studies have shown that estrogen has a protective effect on premenopausal women with metabolic disorders and non-alcoholic fatty liver disease. Estrogen supplements may, at least in theory, prevent the development and progression of NAFLD, while the possibility of inducing cancer limits its application in practice. Phytoestrogen is extracted from plants, whose molecular structure and biological activity are similar to those of mammals' estrogen, therefore, could replace the role of estrogen and prevent the occurrence of adverse reactions to estrogen. This article reviews the published literature related to phytoestrogens and NAFLD as well as suggest the possible mechanisms that may underlie the association between phytoestrogens and NAFLD. It is hoped to provide basis for the treatment of NAFLD with phytoestrogen.

Key words

phytoestrogens - NAFLD - antioxidant - signaling pathway
 

  • References

  • 1 Yildiz F. Phytoestrogens in Functional Foods. CRC Press (Taylor & Francis Ltd); Boca Raton: 2005
    Google Scholar
  • 2 Slavin JL, Lloyd B. Health benefits of fruits and vegetables. Adv Nutr 2012; 3: 506-516
    CrossrefPubMedGoogle Scholar
  • 3 Hashimoto Y, Hamaguchi M, Fukuda T. et al. Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals. Endocrine 2017; 57: 89-97
    CrossrefPubMedGoogle Scholar
  • 4 Ballestri S, Nascimbeni F, Baldelli E. et al. NAFLD as sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fattyliver disease and inherent cardiovascular risk. Adv Ther 2017; 34: 1291-1326
    CrossrefPubMedGoogle Scholar
  • 5 Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH. et al. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010; 9: 402-409
    PubMedGoogle Scholar
  • 6 Bruno S, Maisonneuve P, Castellana P. et al. Incidence and risk factors for nonalcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330 (7497) 932
    CrossrefPubMedGoogle Scholar
  • 7 McKenzie J, Fisher BM, Jaap AJ. et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 2006; 65: 40-44
    CrossrefPubMedGoogle Scholar
  • 8 Hamaguchi M, Kojima T, Ohbora A. et al. Aging is arisk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18: 237-243
    CrossrefPubMedGoogle Scholar
  • 9 Yang JD, Abdelmalek MF, Pang H. et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59: 1406-1414
    CrossrefPubMedGoogle Scholar
  • 10 Yoneda M, Thomas E, Sumida Y. et al. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology 2014; 60: 1792
    PubMedGoogle Scholar
  • 11 Luo F, Ishigami M, Achiwa K. et al. Raloxifene ameliorates liver fibrosis of nonalcoholic steatohepatitis induced by choline-deficient high-fat diet in ovariectomized mice. Dig Dis Sci 2015; 60: 2730-2739
    CrossrefPubMedGoogle Scholar
  • 12 Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657
    CrossrefPubMedGoogle Scholar
  • 13 Klair JS, Yang JD, Abdelmalek MF. et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016; 64: 85-91
    CrossrefPubMedGoogle Scholar
  • 14 Yang JD, Abdelmalek MF, Guy CD. et al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2017; 15: 127-131
    CrossrefPubMedGoogle Scholar
  • 15 Villa E. Role of estrogen in liver cancer. Womens Health (Lond) 2008; 4: 41-50
    CrossrefPubMedGoogle Scholar
  • 16 Yang D, Hanna DL, Usher J. et al. Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis. Cancer 2014; 120: 3707-3716
    CrossrefPubMedGoogle Scholar
  • 17 Jung JH, Kim HS. The inhibitory effect of black soybean on hepatic cholesterol accumulation in high cholesterol and high fat diet-induced non-alcoholic fatty liver disease. Food Chem Toxicol 2013; 60: 404-412
    CrossrefPubMedGoogle Scholar
  • 18 Jeon S, Park YJ, Kwon YH. Genistein alleviates the development of nonalcoholic steatohepatitis in ApoE(–/–) mice fed a high-fat diet. Mol Nutr Food Res 2014; 58: 830-841
    CrossrefPubMedGoogle Scholar
  • 19 Kim JH, Kim YJ. Effects of genistein in combination with conjugated estrogens on endometrial hyperplasia and metabolic dysfunction in ovariectomized mice. Endocr J 2015; 62: 531-542
    CrossrefPubMedGoogle Scholar
  • 20 Huang C, Qiao X, Dong B. Neonatal exposure to genistein ameliorates high-fat diet-induced non-alcoholic steatohepatitis in rats. Br J Nutr 2011; 106: 105-113
    CrossrefPubMedGoogle Scholar
  • 21 Kim MH, Park JS, Jung JW. et al. Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int J Obes (Lond) 2011; 35: 1019-1030
    CrossrefPubMedGoogle Scholar
  • 22 Panneerselvam S, Packirisamy RM, Bobby Z. et al. Soy isoflavones (Glycine max) ameliorate hypertriglyceridemia and hepatic steatosis in high fat-fed ovariectomized Wistar rats (an experimental model of postmenopausal obesity). J Nutr Biochem 2016; 38: 57-69
    CrossrefPubMedGoogle Scholar
  • 23 Park HS, Hur HJ, Kim SH. et al. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice. Mol Nutr Food Res 2016; 60: 1944-1955
    CrossrefPubMedGoogle Scholar
  • 24 Hess D, Igal RA. Genistein downregulates de novo lipid synthesis and impairs cell proliferation in human lung cancer cells. Exp Biol Med (Maywood) 2011; 236: 707-713
    CrossrefPubMedGoogle Scholar
  • 25 Kay HY, Kim WD, Hwang SJ. et al. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding. Antioxid Redox Signal 2011; 15: 2135-2146
    CrossrefPubMedGoogle Scholar
  • 26 Kim YW, Yang YM, Kim TH. et al. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Free Radic Biol Med 2010; 48: 567-578
    CrossrefPubMedGoogle Scholar
  • 27 Mohamed Salih S, Nallasamy P, Muniyandi P. et al. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J Diabetes 2009; 1: 278-287
    CrossrefPubMedGoogle Scholar
  • 28 Kim MH, Kang KS, Lee YS. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br J Nutr 2010; 104: 1333-1342
    CrossrefPubMedGoogle Scholar
  • 29 Gao X, van der Veen JN, Hermansson M. et al. Decreased lipogenesis in white adipose tissue contributes to the resistance to high fat diet-induced obesity in phosphatidylethanolamine N-methyltransferase-deficient mice. Biochim Biophys Acta 2015; 1851: 152-162
    PubMedGoogle Scholar
  • 30 Miller CN, Yang JY, Avra T. et al. A dietary phytochemical blend prevents liver damage associated with adipose tissue mobilization in ovariectomized rats. Obesity (Silver Spring) 2015; 23: 112-119
    CrossrefPubMedGoogle Scholar
  • 31 Ji G, Yang Q, Hao J. et al. Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol 2011; 11: 762-768
    CrossrefPubMedGoogle Scholar
  • 32 Park YJ, Jang YM, Kwon YH. Isoflavones prevent endoplasmic reticulum stress-mediated neuronal degeneration by inhibiting tau hyperphosphorylation in SH-SY5Y cells. J Med Food 2009; 12: 528-535
    CrossrefPubMedGoogle Scholar
  • 33 Anhê FF, Roy D, Pilon G. et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 2015; 64: 872-883
    CrossrefPubMedGoogle Scholar
  • 34 Ohtomo T, Uehara M, Peñalvo JL. et al. Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures. Eur J Nutr 2008; 47: 273-279
    CrossrefPubMedGoogle Scholar
  • 35 Nakatsu CH, Armstrong A, Clavijo AP. et al. Fecal bacterial community changes associated with isoflavone metabolites in postmenopausal women after soy bar consumption. PLoS One 2014; 9: e108924
    CrossrefPubMedGoogle Scholar
  • 36 Hong SW, Choi JY, Chung KS. Culture-based and denaturing gradient gel electrophoresis analysis of the bacterial community from Chungkookjang, a traditional Korean fermented soybean food. J Food Sci 2012; 77: M572-M578
    CrossrefPubMedGoogle Scholar
  • 37 Frankenfeld CL, Atkinson C, Wähälä K. et al. Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein. Eur J Clin Nutr 2014; 68: 526-530
    CrossrefPubMedGoogle Scholar
  • 38 Madak-Erdogan Z, Gong P, Zhao YC. et al. Dietary licorice root supplementation reduces diet-induced weight gain, lipid deposition, and hepatic steatosis in ovariectomized mice without stimulating reproductive tissues and mammary gland. Mol Nutr Food Res 2016; 60: 369-380
    CrossrefPubMedGoogle Scholar
  • 39 Chen KL, Madak-Erdogan Z. Estrogen and Microbiota Crosstalk: Should We Pay Attention?. Trends Endocrinol Metab 2016; 27: 752-755
    CrossrefPubMedGoogle Scholar
  • 40 Dhamija E, Paul SB, Kedia S. et al. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res 2019; 149: 9-17
    CrossrefPubMedGoogle Scholar
  • 41 Divella R, Mazzocca A, Daniele A. et al. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. Int J Biol Sci 2019; 15: 610-616
    CrossrefPubMedGoogle Scholar
  • 42 Sanaei M, Kavoosi F, Dehghani F. et al. Comparative analysis of the effects of 17-beta estradiol on proliferation, and apoptosis in hepatocellular carcinoma Hep G2 and LCL-PI 11 cell lines. Asian Pac J Cancer Prev 2018; 19: 2637-2641
    PubMedGoogle Scholar
  • 43 Lei B, Roncaglia V, Viganò R. et al. Phytoestrogens and liver disease. Mol Cell Endocrinol 2002; 193: 81-84
    CrossrefPubMedGoogle Scholar
  • 44 Chodon D, Banu SM, Padmavathi R. et al. Inhibition of cell proliferation and induction of apoptosis by genistein in experimental hepatocellular carcinoma. Mol Cell Biochem 2007; 297: 73-80
    CrossrefPubMedGoogle Scholar
  • 45 Huang EJ, Wu CC, Huang HP. et al. Apoptotic and anti-proliferative effects of 17beta-estradiol and 17beta-estradiol-like compounds in the Hep3B cell line. Mol Cell Biochem 2006; 290: 1-7
    CrossrefPubMedGoogle Scholar
  • 46 Gu Y, Zhu CF, Iwamoto H. et al. Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J Gastroenterol 2005; 11: 6512-6517
    CrossrefPubMedGoogle Scholar
  • 47 Lee SR, Kwon SW, Lee YH. et al. Dietary intake of genistein suppresses hepatocellular carcinoma through AMPK-mediated apoptosis and anti-inflammation. BMC Cancer 2019; 19: 6
    CrossrefPubMedGoogle Scholar
  • 48 Sanaei M, Kavoosi F, Salehi H. Genistein and trichostatin a induction of estrogen receptor alpha gene expression, apoptosis and cell growth inhibition in hepatocellular carcinoma HepG 2 cells. Asian Pac J Cancer Prev 2017; 18: 3445-3450
    PubMedGoogle Scholar
  • 49 Li S, Li J, Dai W. et al. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death. Br J Cancer 2017; 117: 1518-1528
    CrossrefPubMedGoogle Scholar
  • 50 Wang SD, Chen BC, Kao ST. et al. Genistein inhibits tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. BMC Complement Altern Med 2014; 14: 26
    CrossrefPubMedGoogle Scholar
  • 51 Youssef MM, Tolba MF, Badawy NN. Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells. Sci Rep 2016; 6: 30717
    CrossrefPubMedGoogle Scholar
  • 52 Rigalli JP, Ciriaci N, Arias A. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One 2015; 10: e0119502
    CrossrefPubMedGoogle Scholar
  • 53 Chen P, Hu MD, Deng XF. et al. Genistein reinforces the inhibitory effect of Cisplatin on liver cancer recurrence and metastasis after curative hepatectomy. Asian Pac J Cancer Prev 2013; 14: 759-764
    CrossrefPubMedGoogle Scholar
  • 54 Ma Y, Wang J, Liu L. et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett 2011; 301: 75-84
    CrossrefPubMedGoogle Scholar